Gastric cancer is one of the leading causes of cancer-related death worldwide. Many
patients have inoperable disease at diagnosis or have recurrent disease after resection with …

Gastric cancer (GC) is a leading contributor to global cancer incidence and mortality.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …

Background: The protumor activities of cancer-associated fibroblasts (CAFs) suggest that
they are potential therapeutic targets for the treatment of cancer. The mechanism of CAF …

We analyzed 921 adenocarcinomas of the esophagus, stomach, colon, and rectum to
examine shared and distinguishing molecular characteristics of gastrointestinal tract …

Gastric cancer heterogeneity represents a barrier to disease management. We generated a
comprehensive single-cell atlas of gastric cancer (> 200,000 cells) comprising 48 samples …

Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical
characteristics has been complicated by histological and aetiological heterogeneity. Here …

Gastric cancer, a leading cause of cancer-related deaths, is a heterogeneous disease. We
aim to establish clinically relevant molecular subtypes that would encompass this …

Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict.
Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype …

Purpose To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin
(CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 …

Gastric cancer is the fifth most common cancer and the third most common cause of cancer
death globally. Risk factors for the condition include Helicobacter pylori infection, age, high …